The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial

Hsieh, Ming‐Chia; Tsai, Wan-Hua; Jheng, Yu-Pang; Su, Shih‐Li; Wang, Shuyi; Lin, Chi-Chen; Chen, Yi-Hsing; Chang, Wen‐Wei

doi:10.1038/s41598-018-35014-1

Cited by 118 publications

(142 citation statements)

References 37 publications

(36 reference statements)

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…These results suggested that fragmented CP1563 reduced abdominal fat area, body weight, and BMI in pre-obese subjects. Several human clinical trials showed an anti-obesity effect of the intake of paraprobiotics [25][26][27]. The anti-obesity effect of fragmented CP1563 in this study supported the results of a previous study, which showed the anti-obesity effect of fragmented CP1563 [30].…”

Section: Discussionsupporting

confidence: 90%

“…Few findings have focused on the effects of the oral intake of paraprobiotics on the gut microbial community in obesity prevention [26,27]. In addition, there is no evidence about the effects of fragmented CP1563 on the gut microbial community.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies indicated that paraprobiotics such as Lactobacillus paracasei MCC1849 and Enterococcus faecalis EC-12 were useful for human health, especially with regard to their immunomodulatory effects [23,24]. Furthermore, paraprobiotics have been shown to have anti-obesity effects in human clinical studies [25][26][27].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

Sugawara¹,

Sawada²,

Yanagihara³

et al. 2020

Microorganisms

View full text Add to dashboard Cite

Despite the fact that gut microbiota is closely associated with obesity, few studies have focused on the influences of paraprobiotics as food ingredients on both obesity prevention and the gut microbial community. In this study, we evaluated the effects of fragmented Lactobacillus amylovorus CP1563 (CP1563) as a paraprobiotic for obesity prevention and investigated its effects on the gut microbial community in pre-obese subjects. One hundred sixty-nine healthy subjects with a body mass index from 25.0 to 29.9 kg/m2 ingested beverages with or without the fragmented CP1563 containing 10-hydroxyoctadecanoic acid (10-HOA) for 12 weeks. The changes in abdominal, total, visceral, and subcutaneous fatty areas were significantly lower in the CP1563-10-HOA group than in the placebo group at 12 weeks. Furthermore, 16S rRNA gene sequencing of fecal DNA revealed that the changes in the abundances of the genera Roseburia and Lachnospiraceae;g were significantly greater in the CP1563-10-HOA group than in the placebo group, and the changes in the abundances of the genus Collinsella was significantly smaller in the CP1563-10HOA group than in the placebo group. Our results showed that continuous ingestion of the fragmented CP1563 containing 10-HOA reduced abdominal body fat and affected the gut microbial community in pre-obese healthy subjects. Our findings may contribute to the understanding of the relationship between the anti-obesity effect of paraprobiotics and gut microbiota.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

Sugawara¹,

Sawada²,

Yanagihara³

et al. 2020

Microorganisms

View full text Add to dashboard Cite

show abstract

“…e antioxidant and inflammatory status of the patients were not affected by the probiotic supplementation. Both the strains of L. reuteri exhibited health-promoting property with unique in uences on fecal microbiota and other DM-associated parameters [23].…”

Section: Probiotic Supplementmentioning

confidence: 99%

Do Probiotics Improve the Health Status of Individuals with Diabetes Mellitus? A Review on Outcomes of Clinical Trials

Kesika

Sivamaruthi

Chaiyasut

2019

BioMed Research International

View full text Add to dashboard Cite

Probiotics are now considered as an adjuvant and complementary therapeutic agent for several health complications, especially for metabolic and gastrointestinal disorders because of the influential impact of probiotic consumption on gut microbiota and immunity. Diabetes mellitus (DM) is fourth, in noncommunicable disease category, leading cause of mortality, morbidity, and economic crises in the world. Though several progressions are added in the medical field in recent decades, the treatment and management of diabetic-related health issues are still challenging. The present study summarizes the effects of probiotic supplementation on the health status of diabetic patients. The relevant information was collected from Scopus, PubMed, and Google Scholar. The detailed literature survey revealed that the consumption of probiotic supplementation significantly improved the overall health condition of diabetic patients. Especially, the probiotic intervention improved the fasting blood glucose, insulin sensitivity, and systemic inflammatory and antioxidant status in type 2 diabetic (T2D) patients. Moreover, improvement of gut microbial composition and prevention of bacterial translocation has also been observed in probiotic-supplemented T2D people. Some of the studies evidenced that the supplementation of probiotics can prevent and improve the gestational DM. Nevertheless, some of the studies reported negative results and limitations in the results of clinical trials. However, further studies are mandatory to develop a concrete probiotic-based adjuvant treatment procedure to treat DM.

show abstract

“…Another important approach with associated probiotics (Bifidobacterium, Lactobacillus, and S. thermophilus) for treatment of overweight patients has shown an improvement in lipid profile, as well as insulin sensitivity [82]. Besides, recently Hsieh e collaborators [83] demonstrated that administration of live Lactobacillus reuteri ADR-1 and killed Lactobacillus reuteri ADR-3 strain ameliorated type 2 diabetes mellitus in a clinical trial. The results indicated that the consumption of ADR-1 displayed a reduction effect on serum glycated hemoglobin (HbA1c), triglyceride, and cholesterol levels.…”

Section: Metabolic Syndromementioning

confidence: 99%

Recombinant Probiotics and Microbiota Modulation as a Good Therapy for Diseases Related to the GIT

Jesus¹,

Lima²,

Coelho-Rocha³

et al. 2020

The Health Benefits of Foods - Current Knowledge and Further Development

View full text Add to dashboard Cite

Many diseases that affect the gastrointestinal tract (GIT) have great influence on the quality of life of the majority of patients. Many probiotic strains are being highly studied as a promising candidate due to their beneficial effect reported in the GIT. With the purpose of increasing the beneficial characteristics of some probiotics strains and, consequently, to improve further the reported results, many probiotic strains expressing or encoding different proteins, with anti-inflammatory activities, have been developed. These recombinant strains have been reported as good candidates for the treatment of different pathological conditions, especially colitis and mucositis disease since they have been shown to have positive results and good perspectives for GIT inflammation. Thus, this chapter will first address the aspects of the gastrointestinal tract in humans as well as its microbiota. In a second moment, it will discuss about chronic diseases, mainly the intestinal ones. Finally, it will discuss about probiotics, especially concerning on lactic acid bacteria (LAB), and its action in the prevention and treatment of these diseases. At the final part, we will point out aspects on the development of recombinant strains and the results found in the literature on disease models.

show abstract

The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial

Cited by 118 publications

References 37 publications

Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

Do Probiotics Improve the Health Status of Individuals with Diabetes Mellitus? A Review on Outcomes of Clinical Trials

Recombinant Probiotics and Microbiota Modulation as a Good Therapy for Diseases Related to the GIT

Contact Info

Product

Resources

About